Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.

Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ, Lotan Y.

J Urol. 2010 Jan;183(1):68-75. doi: 10.1016/j.juro.2009.08.115.

PMID:
19913255
2.

Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.

Qian CN, Furge KA, Knol J, Huang D, Chen J, Dykema KJ, Kort EJ, Massie A, Khoo SK, Vanden Beldt K, Resau JH, Anema J, Kahnoski RJ, Morreau H, Camparo P, Comperat E, Sibony M, Denoux Y, Molinie V, Vieillefond A, Eng C, Williams BO, Teh BT.

Cancer Res. 2009 Nov 1;69(21):8256-64. doi: 10.1158/0008-5472.CAN-09-1689.

3.

Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.

Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA.

Clin Cancer Res. 2009 Oct 1;15(19):6008-17. doi: 10.1158/1078-0432.CCR-09-0898.

4.

Staging and reporting of urothelial carcinoma of the urinary bladder.

Cheng L, Montironi R, Davidson DD, Lopez-Beltran A.

Mod Pathol. 2009 Jun;22 Suppl 2:S70-95. doi: 10.1038/modpathol.2009.1. Review.

5.

Rapamycin inhibits growth of cholangiocarcinoma cells.

Okada T, Sawada T, Kubota K.

Hepatogastroenterology. 2009 Jan-Feb;56(89):6-10.

PMID:
19453019
6.

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP.

Nat Genet. 2009 May;41(5):619-24. doi: 10.1038/ng.370.

7.

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL.

Nat Genet. 2009 May;41(5):524-6. doi: 10.1038/ng.371.

8.

Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway.

Schmidt EV, Ravitz MJ, Chen L, Lynch M.

Cell Cycle. 2009 May 1;8(9):1344-51. Review.

9.

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.

Zhou L, Huang Y, Li J, Wang Z.

Med Oncol. 2010 Jun;27(2):255-61. doi: 10.1007/s12032-009-9201-4.

PMID:
19301157
10.

Inactivation of p53 and Pten promotes invasive bladder cancer.

Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C, Abate-Shen C.

Genes Dev. 2009 Mar 15;23(6):675-80. doi: 10.1101/gad.1772909.

11.

The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Hartman TR, Nicolas E, Klein-Szanto A, Al-Saleem T, Cash TP, Simon MC, Henske EP.

Oncogene. 2009 Apr 2;28(13):1594-604. doi: 10.1038/onc.2009.14.

12.

A complex interplay between Akt, TSC2 and the two mTOR complexes.

Huang J, Manning BD.

Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22. doi: 10.1042/BST0370217. Review.

13.

Current status of prognostic immunohistochemical markers for urothelial bladder cancer.

Rosenblatt R, Jonmarker S, Lewensohn R, Egevad L, Sherif A, Kälkner KM, Nilsson S, Valdman A, Ullén A.

Tumour Biol. 2008;29(5):311-22. doi: 10.1159/000170878. Review.

PMID:
18984977
14.

Hypoxia signalling through mTOR and the unfolded protein response in cancer.

Wouters BG, Koritzinsky M.

Nat Rev Cancer. 2008 Nov;8(11):851-64. doi: 10.1038/nrc2501. Review.

PMID:
18846101
15.

Molecular alterations associated with bladder cancer initiation and progression.

Cordon-Cardo C.

Scand J Urol Nephrol Suppl. 2008 Sep;(218):154-65. doi: 10.1080/03008880802291915. Review.

PMID:
18815930
16.

Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.

Feng W, Brown RE, Trung CD, Li W, Wang L, Khoury T, Alrawi S, Yao J, Xia K, Tan D.

Ann Clin Lab Sci. 2008 Summer;38(3):195-209.

PMID:
18715846
17.

Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma.

Baba HA, Wohlschlaeger J, Cicinnati VR, Hilgard P, Lang H, Sotiropoulos GC, Takeda A, Beckebaum S, Schmitz KJ.

Liver Int. 2009 Mar;29(3):399-405. doi: 10.1111/j.1478-3231.2008.01798.x.

PMID:
18492014
18.

Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray.

Harris LD, De La Cerda J, Tuziak T, Rosen D, Xiao L, Shen Y, Sabichi AL, Czerniak B, Grossman HB.

Mol Carcinog. 2008 Sep;47(9):678-85. doi: 10.1002/mc.20420.

19.

Molecular markers in bladder cancer.

Shariat SF, Karam JA, Lerner SP.

Curr Opin Urol. 2008 Jan;18(1):1-8. Review.

PMID:
18090481
20.

PI3K/PTEN signaling in tumorigenesis and angiogenesis.

Jiang BH, Liu LZ.

Biochim Biophys Acta. 2008 Jan;1784(1):150-8. Review.

PMID:
17964232
Items per page

Supplemental Content

Support Center